Cobase 702

Eligible patients’ baseline clinical data including demographic characteristics (age, sex), risk factors (history of hypertension, diabetes mellitus, atrial fibrillation, coronary artery disease, smoking, alcohol consumption), stroke etiologic subtypes, and treatments (anticoagulation agents, antiplatelet agents, statins) were collected. The etiologies of AIS were classified based on the Trial of Org 10172 in Acute Stroke Treatment rating system.^{[17 (link)]} All patients were subjected to routine blood tests within 6 hours of admission. The complete blood counts were measured using a Unicel DxH800 (Beckman Coulter, Brea, CA); lipid profiles, which were measured using a Cobas E702 automatic biochemical analyzer (Roche, Basel Switzerland), were also collected. MPVLR was calculated as the ratio of MPVLR (10³/mm³).

Data about demographic and laboratory features were collected from hospital records or by questionnaire. The blood samples were withdrawn from the antecubital vein of subjects in fasting status, and the level of fasting blood glucose of each individual was detected by hexokinase method by Roche cobase 702. Cases having serum level of fasting blood glucose between 2.2 and 6.1 mmol/L were considered as normality, while serum level of fasting blood glucose <2.2 or >6.1 mmol/L were considered as abnormality.^{[13 (link)–15 (link)]} In addition, the level of glycosylated hemoglobin a1c (HbA1c) was detected by high performance liquid chromatography (HLC-723G7; Tosoh, Tokyo, Japan), which was certified by the National Glycohemoglobin Standardization Program.^{[16 (link)]} The level of HbA1c higher than 6.5% was considered abnormality.^{[17 (link)]}

Data about demographic, laboratory features were collected from hospital records or by questionnaire. Fasting blood samples were collected at baseline in 2010 and again in 2011, 2012, 2013, 2014, 2015, and 2016 every year from the antecubital vein after an 8- to 10-hour overnight fast in vacuum tubes containing ethylene diamine tetraacetic acid. Fasting blood glucose concentrations in each survey were examined with hexokinase method by Roche cobase 702. The same assay was used on all participants at baseline in 2010 and at each follow-up examination from 2011 to 2016. The coefficient of variation using blind quality control specimens was <2.0%. Serum level of fasting blood glucose between 2.2 and 6.1 mmol/L was considered as normality. On the contrary, serum level of fasting blood glucose < 2.2 or higher than 6.2 mmol/L was considered as abnormality.